Labetuzumab anti-DTPA-indium bispecific monoclonal antibody

Drug Profile

Labetuzumab anti-DTPA-indium bispecific monoclonal antibody

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator IBC Pharmaceuticals; Immunomedics
  • Developer Immunomedics
  • Class Antineoplastics; Bispecific antibodies; Monoclonal antibodies; Monoclonal antibody diagnostics; Radiopharmaceutical diagnostics; Radiopharmaceuticals; Recombinant fusion proteins
  • Mechanism of Action Ionising radiation emitters; Radionuclide imaging enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Solid tumours

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Solid-tumours(Diagnosis) in France (IV)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Solid-tumours in USA (IV)
  • 16 Apr 2004 Data presented at the 95th Annual Meeting of the American Association for Cancer Research (AACR-2004) have been added to the Cancer pharmacodynamic sections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top